- Home
- HHS vs XGN Comparison
HHS vs XGN Comparison
Compare HHS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | XGN |
|---|---|---|
| Founded | 1923 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 253.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HHS | XGN |
|---|---|---|
| Price | $3.36 | $6.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 8.0K | ★ 258.6K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $166,841,000.00 | $63,599,000.00 |
| Revenue This Year | $6.54 | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $2.33 | $2.67 |
| 52 Week High | $5.59 | $12.23 |
Technical Indicators
Market Signals| Indicator | HHS | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 24.84 |
| Support Level | $3.04 | $5.93 |
| Resistance Level | $3.35 | $6.80 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 82.11 | 9.12 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.